Avenue Therapeutics, Inc. (ATXI)
OTCMKTS · Delayed Price · Currency is USD
0.4289
+0.027012 (6.72%)
At close: Nov 5, 2026
Avenue Therapeutics Revenue
In the year 2025, Avenue Therapeutics had annual revenue of $1.40M. That makes Avenue Therapeutics the 43,071st largest company in the world by revenue and 5,943rd in the United States.
Revenue
1.40M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
1.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emmaus Life Sciences | 15.53M |
| International Stem Cell | 9.51M |
| AXIM Biotechnologies | 92.90K |
| Enzolytics | 46.59K |
| Halberd | 6.94K |
Avenue Therapeutics News
- 3 months ago - Avenue Therapeutics Quarterly report: Q2 2026 - Filings
- 6 months ago - Avenue Therapeutics Quarterly report: Q1 2026 - Filings
- 7 months ago - Avenue Therapeutics Annual report: Q4 2025 - Filings
- 8 months ago - Avenue Therapeutics enters worldwide license agreement for ATX-04 - TheFly
- 10 months ago - Avenue Therapeutics Transcript: AGM 2025 - Transcripts
- 11 months ago - Avenue Therapeutics Proxy statement: Proxy Filing - Filings
- 11 months ago - Avenue Therapeutics Quarterly report: Q3 2025 - Filings
- 1 year ago - Avenue Therapeutics announces Baergic Bio acquisition by Axsome - TheFly